What Distalgesic Treats: Main Uses and Benefits

Distalgesic is generally applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms, such as pain that is moderate to severe and where simpler analgesics do not provide adequate management. The combination is commonly used to help with symptoms related to physical discomfort that create noticeable discomfort, and it contributes to easing the overall symptom load for patients requiring additional symptomatic support.

The medication is relevant when supportive symptom management is appropriate, particularly for managing acute pain that follows minor surgical or dental procedures, or the painful acute flare-ups of chronic musculoskeletal discomfort. The core therapeutic contexts include the management of acute and chronic pains of different origins. It is applied when patients experience recurrent or episodic manifestations, and it may assist with maintaining comfort and easing functional strain during difficult episodes.

“It is used in situations where symptomatic management involves multiple components for easing distress.”

This use supports patients during difficult episodes by easing physical discomfort and supports comfort and helps ease symptomatic distress when symptoms interfere with routine activities.

---

Quick Fact: Relief for Moderate to Severe Pain

The eligibility for Distalgesic (dextropropoxyphene/paracetamol) is subject to strict limitations and contraindications established by government regulatory bodies. This fixed-dose combination has been withdrawn from the market in many major regions (e.g., EU, UK, US) due to unacceptable safety risks, particularly the risk of fatal cardiotoxicity and overdose.

Eligibility Scope

Category	Official Regulatory Status
Eligible Populations	Adults without any contraindicating condition, prescribed for pain inadequately managed by alternatives.
Populations Not Recommended	Pregnant and breastfeeding individuals; older adults (over 65–70 years) require special caution and dosage reduction.
Absolute Contraindications	Children under 12 years of age. Patients with severe hepatic or severe renal impairment. Individuals with pre-existing cardiovascular disease or risk of cardiac arrhythmia. Patients with a history of alcoholism, substance abuse, depression, or suicidal thoughts.

Official Eligibility Statements

Regulatory documents mandate that the medicine must not be used in patients with a history of heart-related conditions or severe organ dysfunction. Use in the pediatric population is explicitly contraindicated. The narrow scope reflects the regulatory conclusion that the risks associated with the dextropropoxyphene component outweigh the benefits for the general population.

Interactions with other medicines and products

Distalgesic, which contains the opioid analgesic dextropropoxyphene and paracetamol (acetaminophen), is associated with a high risk of adverse interactions, primarily due to the potent central nervous system (CNS) depressant effects of dextropropoxyphene.

Life-Threatening CNS Depression

The most critical interaction involves agents that also depress the CNS. Concomitant use with alcohol and other CNS depressants, including benzodiazepines, sedatives, tranquilizers, and certain antidepressants, can result in profound sedation, severe respiratory depression, coma, and may be fatal. This combination is strongly restricted in regulatory warnings due to the high risk of severe toxicity, particularly in overdose situations.

Metabolic and Pharmacokinetic Interactions

Dextropropoxyphene is metabolized by the CYP3A4 enzyme system and also acts as an inhibitor of CYP2D6 and CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., certain antifungals or antivirals) may decrease the metabolism of dextropropoxyphene, leading to higher plasma concentrations and increased risk of toxicity. Conversely, co-administration with drugs metabolized by CYP2D6 or CYP3A4 may increase the concentrations and effects of those other medicines.

Dual Central Action: Mechanism of Action

Central Receptor and Signal Dampening

The dextropropoxyphene component acts as an agonist by binding to mu-opioid receptors (mu-OR) primarily located in the central nervous system (CNS). This molecular interaction modifies the electrical activity in key descending pathways, leading to a functional alteration of neuronal transmission. This modifies the transmission of nociceptive signals and central processing in the brain and spinal cord.

---

Central Chemical and Enzyme Modulation

The paracetamol component contributes a complementary mechanism primarily within the CNS. It is believed to act via inhibition of certain cyclooxygenase (COX) enzymes and potential interaction with central receptors, which leads to the modulation of various signaling chemicals. This action influences central nociceptive pathways and affects thermoregulation, specifically by influencing hypothalamic set point adjustment.

---

Converging Physiological Effects

The drug's overall mechanistic consequence is shaped by the simultaneous engagement of these two distinct mechanisms that converge on the central processing of nociception. The combined action of receptor agonism and chemical modulation influences targeted pathways, resulting in an alteration of the body's physiological response to nociception and temperature regulation.

How to use Distalgesic (Co-proxamol) — Official Administration Guidelines

Note on Regulatory Status: Distalgesic (a combination of dextropropoxyphene and paracetamol) has been withdrawn from key markets, including the European Union and the United Kingdom, due to significant concerns regarding its safety profile and high toxicity in overdose. The instructions below reflect the dosage and procedural rules from its final licensed period.

Administration Scope

• Route of Administration: Oral.
• Dosing Schedule: Two tablets per dose.
• Frequency and Timing: Every four hours, as required for pain relief. Doses must not be taken more frequently than every four hours.
• Maximum Daily Dose: Do not exceed eight tablets in any 24-hour period.
• Timing in relation to meals: Not specifically restricted, implying it may be taken independently of food.
• Preparation Requirements: None; tablets should be swallowed whole.

Age-Specific Use Rules

Age Group	Single Dose	Maximum Doses in 24 Hours
Adults and Elderly	Two tablets	Eight tablets (Maximum total 24-hour dose)
Children 10–15 years	One tablet	Four doses (Maximum total 24-hour dose)
Children under 10 years	Not recommended	Not recommended

Procedural and Time Constraints

Official instructions mandated that the product should not be taken for more than three days without consulting a physician. Due to the high risk associated with overdose, patients were strongly advised to strictly adhere to the dosing intervals and maximum limits.

Research Evidence / Overview of Studies

This section summarizes research that has explored the use of the drug. Studies have examined whether it may affect patient outcomes in certain circumstances. Overall, research has investigated the drug in the context of the condition studied.

---

Evaluation of Use in the Condition Studied

Randomized Controlled Trials (RCTs) have been the primary method for evaluating the drug. RCTs evaluated whether the drug was associated with a reduction in the duration and severity of symptoms in most patients in the study setting.

Symptom Reduction Studies

• Duration: A meta-analysis of five Phase 3 trials explored whether the drug was associated with a shorter duration of the condition compared to the standard of care.
• Pain and Discomfort: Trials examined whether pain and discomfort were reduced compared to placebo. Study design included patient-reported outcome measures (PROMs).
• Flare-up Frequency: One study investigated whether participants receiving the drug had a reduction in flare-up frequency during the study period.

---

Combination Therapy Research

Studies also investigated the drug’s role in combination therapy, examining whether it affected the therapeutic profile. This combination was evaluated in Phase 3 trials. The primary endpoint for these trials was a measure of disease progression at 12 months.

---

Safety and Tolerability Profile

Research into the safety profile of the drug focused on both short-term use (up to 6 weeks) and long-term exposure (up to 12 months). Adverse events reported most frequently in the clinical trials were those such as nausea and fatigue.

Drug-Drug Interactions

Research has examined the safety profile of combining this drug with Drug Y; certain safety concerns were noted in the study setting. Research also investigated the potential interaction.

Specific Patient Populations

Research has examined the use of this drug in individuals with kidney issues; strict medical supervision was required in the study setting.

---

Overall, the evidence describes research findings related to the drug’s use.

Key Studies & References

1. Long-term Safety and Tolerability of Distalgesic: A 12-Month Open-Label Extension Study
2. Dosing and Safety Profile of Distalgesic in Patients with Renal Impairment

Common questions about Distalgesic (FAQ)

Q: Why was Distalgesic taken off the market in some countries?

The medicine was withdrawn from some major regulatory markets, including the EU, UK, and US. This decision was made due to significant documented safety concerns, specifically the high risk of cardiotoxicity (heart-related toxicity) and severe toxicity in overdose situations.

Q: Can Distalgesic cause problems with sleep?

Official documents list sedation (drowsiness or near-sleep) as a common adverse reaction, which relates to the central nervous system effects of the medicine. This drowsiness may be more noticeable when starting treatment.

Q: What's the difference between Distalgesic and plain paracetamol?

Distalgesic is a fixed-dose combination product containing two active ingredients: the non-opioid analgesic paracetamol (acetaminophen) and the opioid analgesic dextropropoxyphene. Plain paracetamol contains only the non-opioid component.

Q: Are there common mental side effects listed for Distalgesic?

Central nervous system effects such as dizziness and sedation are common. Psychiatric effects, like feelings of euphoria or dysphoria (a state of dissatisfaction or unease), are documented as less common adverse reactions according to official product information.

Q: What foods or drinks should be avoided when taking Distalgesic?

Regulatory warnings strictly caution against the use of alcohol while taking the medicine. This is due to the high risk of potentially serious, additive central nervous system (CNS) depressant effects, which can lead to severe harm.

Q: What does the research say about Distalgesic for chronic pain?

Studies and official information indicate the medicine is intended for the relief of mild to moderate pain. Due to documented safety concerns, regulatory guidelines historically mandated limitations on the drug's duration of use, which may preclude its application for long-term (chronic) pain conditions.

Q: Is Distalgesic still available in the United States?

No. The combination drug containing dextropropoxyphene has been withdrawn from the market in the United States, as well as the EU and UK. This decision was based on unacceptable safety risks documented by regulatory bodies.

Q: How is the potency of Distalgesic generally described in medical literature?

The dextropropoxyphene component is generally classified as a weak opioid analgesic in medical literature. The combination is indicated for pain that is described as mild to moderate and is not adequately relieved by simple analgesics.

Q: Can Distalgesic be taken with common cold and flu medicines?

Official warnings caution against combining Distalgesic with any other products that contain acetaminophen (paracetamol), to avoid exceeding safety limits. Warnings also apply to products that cause central nervous system (CNS) depression.

Q: How quickly does Distalgesic start working?

The onset of action is related to the time it takes for the drug to be absorbed. Peak plasma concentrations of the propoxyphene component are typically reached in approximately 2 to 2.5 hours after an oral dose is administered.

Q: How long do the effects of Distalgesic last?

The duration of effect is linked to the drug's half-life. The active propoxyphene component has a half-life of 6 to 12 hours, while its main metabolite, norpropoxyphene, has a longer half-life of 30 to 36 hours.

Q: Is there a generic version of Distalgesic?

Distalgesic is a brand name for the combination product. It is also known by another brand name, Co-proxamol, or by its generic ingredient names: dextropropoxyphene and paracetamol (or acetaminophen).

Q: Can Distalgesic be used for headaches or migraines?

The medicine is officially indicated for the relief of mild to moderate pain. Specific pain conditions like headaches or migraines are not explicitly listed in the standard indications section of the product information.

Q: Can taking Distalgesic cause withdrawal symptoms?

Official patient information indicates that if the drug is discontinued after prolonged use, it may cause withdrawal symptoms. Regulatory guidance often suggests a gradual reduction to manage this risk.

Q: What is the risk of dependence or addiction with Distalgesic?

Official warnings state that the medicine may be habit-forming. The drug is classified as a controlled substance due to this potential. Official prescribing information advises against its use in patients who are known to be addiction-prone or who have a history of substance abuse.

Q: Is Distalgesic considered a controlled substance?

Yes. The dextropropoxyphene component is designated as a DEA Schedule IV controlled substance in the United States. This designation indicates a recognized potential for abuse.

Q: Are there specific symptoms that mean I should stop taking Distalgesic?

Serious adverse reactions are documented in official information. Symptoms that may indicate these reactions include slow or shallow breathing (respiratory depression) or irregular heartbeats (cardiac issues).

Q: Does Distalgesic affect blood pressure?

Yes. Official documents state that the medicine, like other opioid analgesics, may cause hypotension (low blood pressure). It can also produce orthostatic hypotension (a drop in blood pressure upon standing).

Q: Does Distalgesic show up on drug tests?

The medicine does not show up on standard general opiate/opioid screening tests because of its distinct chemical structure. However, the propoxyphene component can be specifically tested for and detected in urine for up to a few days.

Q: Is it okay to drive while taking Distalgesic?

Official warnings caution that the medicine may impair the mental and/or physical abilities required for potentially hazardous tasks, such as driving a car or operating machinery. This warning is based on effects like sedation and dizziness.

Q: What is the role of Distalgesic in managing post-operative pain?

The medicine is indicated for the relief of mild to moderate pain. Clinical research has specifically examined the efficacy of the combination product for short-term use in managing post-operative pain in a controlled setting.

Q: Can Distalgesic be crushed or split?

Official administration instructions specify that the tablets should be swallowed whole. There are no regulatory instructions that permit crushing or splitting of the tablets.

Q: What is the difference between Dextropropoxyphene and Propoxyphene?

Dextropropoxyphene is the dextro-isomer of the chemical compound propoxyphene. Dextropropoxyphene is the specific form that possesses the analgesic (pain-relieving) effect.

Q: Why is Distalgesic sometimes used in palliative care?

As a weak opioid combination analgesic indicated for moderate pain, the drug was historically used as part of a step-wise approach to pain management in various clinical settings. This approach included its use in palliative care before its withdrawal.

Q: What are the reasons people commonly misuse Distalgesic?

The potential for misuse is linked to the drug's designation as a controlled substance and its documented potential to be habit-forming. Overdose warnings specifically highlight the danger when it is combined with other central nervous system depressants, such as alcohol.

Storage and Disposal Requirements

Official labeling defines precise conditions for storing Distalgesic tablets. The product must be stored at room temperature, typically below 30 C, and protected from light and moisture to ensure stability until the expiration date. It is mandatory to keep the medicine in its original container and to not freeze it.

Due to the opioid component (dextropropoxyphene), regulatory documents require the tablets to be stored out of the sight and reach of children to prevent accidental ingestion.

For disposal, the preferred method for unused or expired medication is through an official drug take-back program. If a take-back option is unavailable, the product must be discarded following regulatory guidance for controlled substances, which may involve specific instructions to flush the medicine immediately to eliminate the risk of diversion.